A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

Abbott1,000 enrolled

Overview

This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

1,000

Conditions

Prostate Cancer

Interventions

AtrasentanDRUG

Eligibility

Sex: MALEMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of prostate cancer. * Rising PSA while on hormonal therapy or following surgical castration. * Documented evidence of metastatic disease. Exclusion Criteria: * Have received cytotoxic chemotherapy. * Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months.

Locations (232)

Outcomes

Primary Outcomes

The primary objective of this study is to evaluate safety and efficacy as measured by time-to-disease progression

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Urology Centers Of Alabama

Homewood, Alabama, United States

Alaska Clinical Research Center, LLC

Anchorage, Alaska, United States

Advanced Clinical Trials

Tucson, Arizona, United States

Arkansas Urologial Associates, PA

Little Rock, Arkansas, United States

Robin V. Smith, MD

Chula Vista, California, United States

Urology Associate Of Central California

Fresno, California, United States

South Valley Medical Plaza

Gilroy, California, United States

San Diego Urology Center

La Mesa, California, United States

UCLA School Of Medicine

Los Angeles, California, United States

Hillcrest Urological Medical Group, Inc.

San Diego, California, United States

...and 222 more locations